Deal strengthens HiberCell’s balance sheet, accelerates clinical programs and expands pre-clinical pipeline through the integration of next generation artificial intelligence (AI) and machine learning (ML) strategies...read more
Category - Drug discovery
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Company is pioneering true “search and replace” gene editing to address the fundamental genetic causes of disease, restore normal gene function, and potentially provide patients with long-lasting cures Company led by...read more
FAIR Data or the Journey Towards Data-Centricity – Pushing Towards Making Data Discoverable, Accessible, Interoperable, and Reusable
Data is the blood being pumped through the organism of personalized medicine and will be – as has always been – the key to the identification of novel biomarkers and potential new therapeutics. We have never...read more
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ — Invitae...read more
